FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)

View source ↗

Summary

FDA announces a supplemental application outcome for METHYLIN (methylphenidate hydrochloride) from Shionogi Inc., resulting in a labeling change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• METHYLIN (Methylphenidate hydrochloride)

Snippet

SUPPL AP for METHYLIN (METHYLPHENIDATE HYDROCHLORIDE)